Skip to main content
Clinical Trials/IRCT20180802040678N4
IRCT20180802040678N4RecruitingPhase 3

Evaluation of the effects of Losartan in patients with corona virus disease 2019

Tabriz University of Medical Sciences0 sites100 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Laboratory (RT-PCR of oropharyngeal swab) confirmed COVID-19
  • Stable hemodynamic condition
  • Blood pressure =130/85 mmHg

Exclusion Criteria

  • Patient's critical condition
  • Cough exacerbation after initiating Losartan
  • Increasing blood potassium levels or high baseline potassium levels
  • Shock or decreasing blood pressure = 90/60 mmHg after Losartan initiating
  • Acute hepatic failure
  • Acute renal failure
  • Bilateral renal artery stenosis
  • History of uncontrolled hypertension
  • Pregnancy and lactation
  • History of treatment with ACE inhibitors and ARB inhibitors
  • Treatment with phenobarbital, rifampin and fluconazole

Investigators

Similar Trials